Risks of venous thromboembolic complications in related to combined oral contraceptives
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.207
Abstract
Hormonal contraception is the most popular and effective reversible method for preventing unwanted pregnancy exerting multiple prophylactic and therapeutic effect along with contraceptive activity. The main adverse coupled to combined oral contraceptives (COCs) is its impact on the hemostasis and increased risk of venous thromboembolic complications. A great evolutionary path has been travelled after beginning application of hormonal contraception to reduce dose of its estrogen component and improving quality of gestagen component. Nevertheless, thrombotic complications related to COCs use still remain a pressing issue not only due to disease severity and high mortality rate from pulmonary embolism (PE), but also due to the difficulties in its timely diagnostics. Here we describe a clinical case of a 19-year-old patient suffering from vena cava inferior thrombosis complicated by PE after using COCs.
About the Authors
K. A. Gabelova
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Karina A. Gabelova – MD, PhD, Associate Professor, Department of Obstetrics, Gynecology and Neonatology
6–8 Lev Tolstoy Str., Saint Petersburg 197022
N. A. Shabanova
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Nadezhda A. Shabanova – MD, PhD, Assistant, Department of Obstetrics, Gynecology and Neonatology
6–8 Lev Tolstoy Str., Saint Petersburg 197022
V. F. Bezhenar
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Vitaly F. Bezhenar – MD, Dr Sci Med, Professor, Head of the Department of Obstetrics, Gynecology and Neonatology; Chief External Expert in Obstetrics and Gynecology of the Health Committee of Saint Petersburg
6–8 Lev Tolstoy Str., Saint Petersburg 197022
E. E. Zvartau
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Edvin E. Zvartau – MD, Dr Sci Med, Professor, Director of Valdman Institute of Pharmacology, Head of the Department of Pharmacology
6–8 Lev Tolstoy Str., Saint Petersburg 197022
Yu. A. Akishina
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Yulia A. Akishina – 4th year Student
6–8 Lev Tolstoy Str., Saint Petersburg 197022
References
1. Petrov Yu.A., Shatalov A.E., Kupina A.D. Hormonal contraception: safety and tolerability. [Gormonal'naya kontracepciya: bezopasnost' i perenosimost']. Mediko-farmacevticheskij zhurnal Pul's. 2019;21(9):37–43. (In Russ.). http://doi.org/10.26787/nydha-2686-6838-2019-21-9-37-43..
2. Ledina A.V., Korolenkova L.N., Ledin E.V. Cancer risks and benefits of hormonal contraception: a literature review and practical issues. [Onkologicheskie riski i pol'za gormonal'noj kontracepcii: literaturnyj obzor i prakticheskie voprosy]. Ginekologiya. 2019;21(1):75–9. (In Russ.).
3. Guidelines for contraception. Ed. Prof. V.N. Prilepskaya. 4 th ed. [Rukovodstvo po kontracepcii. Pod red. prof. V.N. Prilepskoj. 4-e izd]. Moscow: MEDpress-inform, 2017. 464 p. (In Russ.).
4. Prilepskaya V.N., Abakarova P.R., Yarotskaya E.L. Modern contraception and women's quality of life. [Sovremennaya kontracepciya i kachestvo zhizni zhenshchiny]. Doktor.Ru. 2017;3(132):37–42. (In Russ.).
5. Podzolkova N.M., Koloda Yu.A., Rogovskaya S.I., Korennaya V.V. Modern contraception: new opportunities, safety criteria, consulting basics. [Sovremennaya kontracepciya. Novye vozmozhnosti, kriterii bezopasnosti, osnovy konsul'tirovaniya]. Moscow: GEOTAR-Media, 2019. 117 p. (In Russ.).
6. Dobrokhotova Yu.E., Borovkova E.I. The personalized approach to choosing a contraceptive: weighing the pros and cons. [Personalizirovannyj podhod k vyboru kontraceptiva: vzveshivaem vse za i protiv]. Ginekologiya. 2017;19(3):40–4. (In Russ.).
7. Tikhomirov A.L., Yudina T.A., Burchakov D.I. Combined oral contraceptives in improving quality of young women’s life. [Kombinirovannye oral'nye kontraceptivy v aspektah povysheniya kachestva zhizni molodyh zhenshchin]. Medicinskij alfavit. 2019;1(376):15–18. (In Russ.). https://doi.org/10.33667/2078-5631-2019-1-1(376)-15-18.
8. Unanyan A.L., Nikonets A.D., Aminova L.N. et al. Noncontraceptive effects of combined oral contraceptives: benefits and risks of use. [Nekontraceptivnye effekty kombinirovannyh oral'nyh kontraceptivov: preimushchestva i riski primeneniya]. Ginekologiya. 2017;19(2):69–74. (In Russ.).
9. Farris M., Bastianelli C., Rosato E. et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2 effects on hemostasis. Exp Rev Clin Pharmacol. 2017;10(10):1129–44. https://doi.org/10.1080/17512433.2017.1356718.
10. Medical acceptability criteria for contraceptive use, 5th edition. [Medicinskie kriterii priemlemosti dlya ispol'zovaniya metodov kontracepcii, 5-e izdanie]. VOZ, 2015. 192 р. (In Russ.). Available at: https://www.euro.who.int/__data/assets/pdf_file/0005/348116/MEC-merged.pdf.
11. Makatsariya A.D., Bitsadze V.O., Akinshina S.V. Thrombosis and thromboembolism in the obstetric and gynecological clinic: Molecular genetic mechanisms and strategies for the prevention of thromboembolic complications: A guide for physicians. [Trombozy i tromboembolii v akushersko-ginekologicheskoj klinike: Molekulyarnogeneticheskie mekhanizmy i strategiya profilaktiki tromboembolicheskih oslozhnenij: Rukovodstvo dlya vrachej]. Moscow: MIA, 2007. 1064 p. (In Russ.).
12. Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 2019;48(5):297–307. https://doi.org/10.1016/j.jogoh.2019.02.006.
13. Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril. 2016;106(6):1289–94. https://doi.org/10.1016/j.fertnstert.2016.08.039.
14. Plu-Bureau G., Maitrot-Mantelet L., Hugon-Rodin J. et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27(1):25–34. https://doi.org/10.1016/j.beem.2012.11.002.
15. Khamani N.M., Saidova R.A., Khamani I.V. et al. Retrospective analysis of risk factors for thrombotic events due to the use of combined oral contraceptives. [Retrospektivnyj analiz faktorov riska tromboticheskih oslozhnenij pri prieme kombinirovannyh oral'nyh kontraceptivov]. Akusherstvo i ginekologiya. 2019;(6):108–14. https://doi.org/10.18565/aig.2019.6.108-114. (In Russ.).
16. Makatsariya A.D., Bitsadze V.O., Blinov D.V., Korabelnikov D.I. Information on the combined hormonal contraceptives (CHC) containing the dienogest + ethinyl estradiol combination (Jeanine® ). [Informaciya o kombinirovannyh gormonal'nyh kontraceptivnyh preparatah (KGK), soderzhashchih kombinaciyu dienogest + etinilestradiol (lekarstvennyj preparat Zhanin)]. Obstetrics, Gynecology and Reproduction. 2019;13(1):7–12. (In Russ.). https://doi.org/10.17749/2313-7347.2019.13.1.007-012.
17. Manukhin I.B., Tumilovich L.G., Gevorkyan M.A. Gynecological endocrinology. Clinical lectures: a guide for physicians. 3rd ed. [Ginekologicheskaya endokrinologiya. Klinicheskie lekcii: rukovodstvo dlya vrachej. 3-e izd]. Moscow: GEOTAR-Media, 2013. 272 p. (In Russ.).
18. Venous thromboembolism and pulmonary embolism. Eds. I.N. Bokareva, L.V. Popova. 2nd ed. [Venoznyj tromboembolizm i tromboemboliya legochnoj arterii. Pod red. I.N. Bokareva, L.V. Popovoj. 2-e izd]. Moscow: MIA, 2013. 512 p. (In Russ.).
19. Shabanova N.A., Zainulina M.S. Modern approaches to prevention of thromboembolic complications in pregnancy. [Sovremennye podhody k profilaktike tromboembolicheskih oslozhnenij pri beremennosti]. Zhurnal akusherstva i zhenskih boleznej. 2011;60(3):161–8. (In Russ.).
20. Bokeria L.A. Zatevakhin I.I., Kirienko A.I. et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. [Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembolicheskih oslozhnenij]. Flebologiya. 2015;9(4–2):1–52. (In Russ.).
21. Ovchinnikov Yu.V., Panfilov D.N., Zelenov M.V. et al. Pulmonary thromboembolism in women using oral hormonal contraceptives. [Tromboemboliya legochnoj arterii u zhenshchin, prinimayushchih peroral'nye gormonal'nye kontraceptivy]. Klinicheskaya medicina. 2015;93(10):58–66. (In Russ.).
22. Bokarev I.N., Lyusov V.A., Kirienko A.I. et al. Venous thrombosis and pulmonary embolism. [Venoznye trombozy i tromboemboliya legochnyh arterij]. Rossijskij kardiologicheskij zhurnal. 2011;16(4):5–12. (In Russ.).
23. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(43):3033–80, 3069a–3069k. https://doi.org/10.1093/eurheartj/ehu283.
24. Bezhenar V.F., Tsvelev Yu.V., Levshankov A.I. et al. Thromboembolic complications in obstetric and gynecological practices. [Tromboembolicheskie oslozhneniya v akushersko-ginekologicheskoj praktike]. Zhurnal akusherstva i zhenskih boleznej. 2004;53(1):55–72. (In Russ.).
25. Gordeev N.A., Sedov V.M., Balluzek F.V. et al. Prevention of pulmonary embolism by clipping the inferior vena cava and iliac veins: indications, technique, immediate and long-term results. [Profilaktika tromboembolii legochnoj arterii klipirovaniem nizhnej poloj i podvzdoshnyh ven: pokazaniya, tekhnika, blizhajshie i otdalennye rezul'taty]. Novosti hirurgii. 2010;18(4):157–64. (In Russ.).
26. Kareva E.N. Thrombosis and gestagens. [Trombozy i gestageny]. Doktor.Ru. 2019;7(162):57–64. (In Russ.). https://doi.org/10.31550/1727-2378-2019-162-7-57-64.
27. Shishkova V.N. Pitfalls of modern contraception: focus on the risk of thrombosis and metabolic disorders. [Podvodnye kamni sovremennoj kontracepcii: fokus na risk trombozov i metabolicheskie narusheniya]. Zemskij vrach. 2012;(3):45–52. (In Russ.).
28. Stocco B., Fumagalli H.F., Franceschini S.A. et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables. An observational preliminary study. Medicine (Baltimore). 2015;94(4):e385. https://doi.org/10.1097/MD.0000000000000385.
29. Palacios S., Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Exp Opin Drug Safety. 2016;15(11):1515–25. https://doi.org/10.1080/14740338.2016.1223041.
30. Barsoum M.K., Heit J.A., Ashrani A.A. et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res. 2010;126(5):373–8. https://doi.org/10.1016/j.thromres.2010.08.010.
31. Lidegaard O., Nielsen L.H., Skovlund C.W. et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ. 2011;343:d6423. https://doi.org/10.1136/bmj.d6423.
32. Lidegaard О. Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives. BJOG. 2018;125(8):929–31. https://doi.org/10.1111/14710528.15211.
Review
For citations:
Gabelova K.A., Shabanova N.A., Bezhenar V.F., Zvartau E.E., Akishina Yu.A. Risks of venous thromboembolic complications in related to combined oral contraceptives. Obstetrics, Gynecology and Reproduction. 2021;15(6):777-787. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.207
Views:
939
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
